Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

被引：0
|
作者：
Orlando, Laura [1 ]
Cardillo, Anna [1 ]
Ghisini, Raffaella [1 ]
Rocca, Andrea [1 ]
Balduzzi, Alessandra [1 ]
Torrisi, Rosalba [1 ]
Peruzzotti, Giulia [1 ]
Goldhirsch, Aron [1 ]
Pietri, Elisabetta [1 ]
Colleoni, Marco [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [41] Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer
    Gil, M.
    Martin, M.
    Antolin, S.
    Trigo, J. M.
    Guerrero, A.
    Vidal, L.
    Urruticoechea, A.
    Pandiella, A.
    Hernando, A.
    Ocana, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S180
  • [42] The Impact of Trastuzumab on the Pulmonary Artery Systolic Pressure in Patients With HER-2 Positive Breast Cancer
    Abdulelah, Zaid A.
    Khrais, Mohammad Z.
    Ghalayni, Ruba A.
    Al-Khalili, Faris
    Alqaisieh, Mohammad
    AbuAlSha'r, Mu'taz F.
    Abdulelah, Ahmed A.
    Abandeh, Yazan S.
    Al-Rimawi, Dalia
    Hamam, Ismail R.
    CIRCULATION, 2022, 146
  • [43] A prognostic model to predict the risk of developing brain metastasis in patients treated with trastuzumab for HER-2 positive metastatic breast cancer
    Pansegran, GK
    Lohrisch, CA
    Bajdik, CD
    Speers, CH
    Baerg, BE
    Barnett, JB
    Glemon, KA
    Olivotto, IA
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S74 - S74
  • [44] Phase I study of sunitinib (S) in combination with metronomic dosing of cyclophosphamide and methotrexate (CM) in patients with metastatic breast cancer (MBC)
    Lyandres, J.
    Moasser, M. M.
    Melisko, M.
    Goga, A.
    Park, J. W.
    Rugo, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] The combination of weekly trastuzumab plus vinorelbine may be preferable regimen in HER-2 positive breast cancer patients with brain metastasis
    Mutlu, Hasan
    Buyukcelik, Abdullah
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (04) : 310 - 312
  • [46] Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
    Mundi, P. S.
    Lee, S.
    Chi, D.
    Bhardwaj, A.
    Makower, D.
    Cigler, T.
    Crew, K. D.
    Hershman, D. L.
    Califano, A.
    Silva, J.
    Kalinsky, K. M.
    CANCER RESEARCH, 2017, 77
  • [47] Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    ONCOLOGIST, 2006, 11 (08): : 857 - 867
  • [48] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [49] Low incidence of cardiac events in an EORTC phase II study of CMF in combination with Trastuzumab in women with HER-2 positive metastatic breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 170 - 170
  • [50] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission
    Haq, R.
    Gulasingam, P.
    CURRENT ONCOLOGY, 2016, 23 (02) : 91 - 95
12345